P
Paul B. Fisher
Researcher at Virginia Commonwealth University
Publications - 486
Citations - 35304
Paul B. Fisher is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 80, co-authored 449 publications receiving 31149 citations. Previous affiliations of Paul B. Fisher include Discovery Institute & Columbia University Medical Center.
Papers
More filters
Book ChapterDOI
Molecular-Genetic Imaging of Cancer
Il Minn,Mitchell E. Menezes,Siddik Sarkar,Keerthi Yarlagadda,Swadesh K. Das,Luni Emdad,Devanand Sarkar,Paul B. Fisher,Martin G. Pomper +8 more
TL;DR: This chapter will provide an introduction to the components of molecular-genetic imaging and recent advances on each component leading to safe, efficient clinical applications for detecting cancer.
Journal ArticleDOI
MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein
TL;DR: Melanoma differentiation associated gene-9 ( mda-9) (also known as Syntenin-1 and SDCBP (Syndecan binding protein)) was identified by subtraction hybridization as a novel gene displaying differential temporal expression during differentiation of melanoma.
Journal Article
Transfer of a dominant-acting tumor-inducing oncogene from human prostatic carcinoma cells to cloned rat embryo fibroblast cells by DNA-transfection.
TL;DR: The present study indicates that the human prostatic carcinoma cell line, LNCaP, contains a dominant-acting tumor-inducing oncogene which does not induce morphological transformation of CREF-Trans 6 or NIH-3T3 cells in monolayer culture.
Journal ArticleDOI
Adenovirus-mediated hPNPase(old-35) gene transfer as a therapeutic strategy for neuroblastoma.
TL;DR: The data demonstrate that efficient adenoviral transduction of neuroblastoma cells and robust transgene expression are feasible objectives, and suggest that combination with the PEG‐3 promoter holds promise for creating a potent and selective Neuroblastoma therapeutic.
Book ChapterDOI
New Insights Into Beclin-1: Evolution and Pan-Malignancy Inhibitor Activity.
Stephen L. Wechman,Anjan K. Pradhan,Rob DeSalle,Swadesh K. Das,Luni Emdad,Devanand Sarkar,Paul B. Fisher +6 more
TL;DR: Experimental evidence suggests that Beclin-1 inhibits tumor formation, angiogenesis, and metastasis alone and in cooperation with the tumor suppressive molecules UVRAG, Bif-1, Ambra1, and MDA-7/IL-24 via diverse mechanisms of action.